Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma.

ABSTRACT:

Background

Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed and treated in advanced tumor stages with poor prognosis. More effective screening programs and novel therapeutic means are urgently needed. Recent studies have regarded tight junction protein claudin 18.2 (CLDN18.2) as a candidate target for cancer treatment, and zolbetuximab (formerly known as IMAB362) has been developed against CLDN18.2. However, there are few data reported thus far related to the clinicopathological characteristics of CLDN18.2 expression for PDAC.

Aim

To investigate the expression of CLDN18.2 in PDAC patients and subsequently propose a new target for the treatment of PDAC.

Methods

The Cancer Genome Atlas, Genotype-Tissue Expression, Gene Expression Omnibus, and European Gen

SUBMITTER: Wang X 

PROVIDER: S-EPMC9305579 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature